Biopharmaceuticals reflect the rapid progress achieved in modern biomedical research. This area has also become one of the main criteria for assessing the development level of biotechnology for a particular country. Although it has been only three decades since the first biopharmaceutical, recombinant human insulin, was licensed by the US Food and Drug Administration, the biopharmaceutical industry has become the fastest growing, most dynamic and technology-intensive sector in the biomedical field. Since the licensing of recombinant human interferon α1b in 1989, the biopharmaceutical industry in China has gone through initial developments and gradually entered a period of rapid growth. This paper provides an overview of the status and development trends of biopharmaceuticals in China, and compares them with those observed in developed countries.
Corresponding Author(s):
Wang Junzhi,Email:wangjz@nicpbp.org.cn
引用本文:
. The biopharmaceutical industry in China: history and future perspectives[J]. Frontiers of Medicine, 0, (): 101-111.
Kai Gao, Junzhi Wang. The biopharmaceutical industry in China: history and future perspectives. Front Med, 0, (): 101-111.
For the prevention of Helicobacter pylori infection
Injections
*Recombinant hepatitis E vaccine
E. coli
For the prevention of hepatitis E
Injections
Tab.1
1
European Directorate for Quality Medicines & Healthcare (EDQM). Recombinant DNA technology products of. In: EDQM. General Monograph, European Pharmacopoeia 7.0. Strasbourg , France:EDQM,2011: 692-693
2
Wang JZ. Development and quality control of biopharmaceuticals.2nd Ed. Beijing: Science Press, 2007:76-77 (in Chinese)
3
Li XY, Wang HG. Advance the biotechnology, leading the bio-economy. Beijing: China Medical Science Press, 2005: 8-20 (in Chinese)
4
http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM164641.pdf(Access on January 18, 2012)
5
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080402.htm (Access on January 18, 2012)
6
http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM071118.pdf(Access on January 18, 2012)
7
http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts (Access on January 18, 2012)
8
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts (Access on January 18, 2012)
9
Hu XW, Ma QJ. The present and the future of bioindustry: biopharmaceuticals. In: Annual Report on Bioindustry in China (2006) . Beijing: Chemical Industry Press, 2007: 45-74 (in Chinese)
10
http://knol.google.com/k/krishan-maggon/top-ten-twenty-best-selling-drugs-2010/3fy5eowy8suq3/141# (Access on January 18, 2012)
11
http://www.sfda.gov.cn/WS01/CL0001(Access on January 18, 2012)
12
Li XY, Wang HG. Advance the biotechnology, leading the bio-economy. Beijing: China Medical Science Press, 2005: 69 (in Chinese)
13
Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004; 22(11): 1393-1398 doi: 10.1038/nbt1026 pmid:15529164
14
Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, Wang YJ, Ai X, Hu YM, Tang Q, Yao X, Yan Q, Xian YL, Wu T, Li YM, Miao J, Ng MH, Shih JW, Xia NS. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376(9744): 895-902 doi: 10.1016/S0140-6736(10)61030-6 pmid:20728932
15
Barros FF, Powe DG, Ellis IO, Green AR. Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology 2010; 56(5): 560-572 doi: 10.1111/j.1365-2559.2010.03494.x pmid:20459566
16
Scardino A, Alimandi M, Correale P, Smith SG, Bei R, Firat H, Cusi MG, Faure O, Graf-Dubois S, Cencioni G, Marrocco J, Chouaib S, Lemonnier FA, Jackson AM, Kosmatopoulos K. A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge. Cancer Res 2007; 67(14): 7028-7036 doi: 10.1158/0008-5472.CAN-06-3998 pmid:17638916
17
Brockhoff G, Heiss P, Schlegel J, Hofstaedter F, Knuechel R. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. Cytometry 2001; 44(4): 338-348 doi: 10.1002/1097-0320(20010801)44:4<338::AID-CYTO1125>3.0.CO;2-V pmid:11500850
18
Choi DH, Woo JK, Choi Y, Seo HS, Kim CW. A novel chimeric DNA vaccine: enhancement of preventive and therapeutic efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock protein 70 gene. Mol Med Report 2011; 4(5): 885-890 pmid:21725596
19
Wang XJ, Wang ZB, Wei HF, Wu XL, Wang L, Yu YL, Wang LY. Enhancement of HSP-MUC1 antitumor activity by type C CpG-ODN BW005. J Cell Mol Immunol (Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi) 2007; 23(4): 338-340 (in Chinese) pmid:17428390
20
Li D, Li H, Zhang P, Wu X, Wei H, Wang L, Wan M, Deng P, Zhang Y, Wang J, Liu Y, Yu Y, Wang L. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity. Eur J Immunol 2006; 36(5): 1324-1336 doi: 10.1002/eji.200535490 pmid:16619287
21
Wang XY, Zhang XX, Yao X, Jiang JH, Xie YH, Yuan ZH, Wen YM. Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine. Vaccine 2010; 28(51): 8169-8174 doi: 10.1016/j.vaccine.2010.09.093 pmid:20937312
22
Xu DZ, Zhao K, Guo LM, Li LJ, Xie Q, Ren H, Zhang JM, Xu M, Wang HF, Huang WX, Bai XF, Niu JQ, Liu P, Chen XY, Shen XL, Yuan ZH, Wang XY, Wen YM. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE 2008; 3(7): e2565 doi: 10.1371/journal.pone.0002565 pmid:18596958
23
Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ. Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis. Nature 2008; 454(7205): 776-779 pmid:18594509
24
He B, Santamaria R, Xu W, Cols M, Chen K, Puga I, Shan M, Xiong H, Bussel JB, Chiu A, Puel A, Reichenbach J, Marodi L, D?ffinger R, Vasconcelos J, Issekutz A, Krause J, Davies G, Li X, Grimbacher B, Plebani A, Meffre E, Picard C, Cunningham-Rundles C, Casanova JL, Cerutti A. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol 2010; 11(9): 836-845 doi: 10.1038/ni.1914 pmid:20676093
25
Giamas G, Filipovi? A, Jacob J, Messier W, Zhang H, Yang D, Zhang W, Shifa BA, Photiou A, Tralau-Stewart C, Castellano L, Green AR, Coombes RC, Ellis IO, Ali S, Lenz HJ, Stebbing J. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med 2011; 17(6): 715-719 doi: 10.1038/nm.2351 pmid:21602804
26
Pan X, Zhou T, Tai YH, Wang C, Zhao J, Cao Y, Chen Y, Zhang PJ, Yu M, Zhen C, Mu R, Bai ZF, Li HY, Li AL, Liang B, Jian Z, Zhang WN, Man JH, Gao YF, Gong WL, Wei LX, Zhang XM. Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nat Med 2011; 17(6): 708-714 doi: 10.1038/nm.2369 pmid:21572428
27
Zhou L, Li F, Xu HB, Luo CX, Wu HY, Zhu MM, Lu W, Ji X, Zhou QG, Zhu DY. Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat Med 2010; 16(12): 1439-1443 doi: 10.1038/nm.2245 pmid:21102461
28
Zhao WJ, Gao ZY, Wei H, Nie HZ, Zhao Q, Zhou XJ, Wang YX. Spinal D-amino acid oxidase contributes to neuropathic pain in rats. J Pharmacol Exp Ther 2010; 332(1): 248-254 doi: 10.1124/jpet.109.158816 pmid:19828879
